Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • KRAS mutations

    - PMLiVE

    MSD receives NICE recommendation for Keytruda in advanced endometrial cancer

    More than 9,700 new cases of endometrial cancer are diagnosed every year in the UK

    - PMLiVE

    Merck unveils $3bn cost-cutting plan to support pipeline and new product launches

    A new restructuring programme has been approved to support the initiative

    - PMLiVE

    MSD receives MHRA approval for adult-specific pneumococcal vaccine Capvaxive

    Illnesses caused by Streptococcus pneumoniae are currently considered a major public health problem by WHO

    - PMLiVE

    Merck gains rights to Hengrui’s heart disease candidate in deal worth almost $2bn

    Cardiovascular diseases result in an estimated 17.9 million global deaths each year

    - PMLiVE

    MSD’s Welireg recommended by NICE to treat rare von Hippel-Lindau disease

    Approximately one in every 70,000 people are affected by the tumour-causing genetic disease

    - PMLiVE

    MSD and Astex announce expansion to oncology drug discovery collaboration

    Astex will receive $35m upfront plus milestone payments totalling $500m per programme

    - PMLiVE

    MSD and Eisai’s combination therapy recommended by NICE for advanced endometrial cancer

    More than 9,700 people are diagnosed with womb cancer each year in the UK

    - PMLiVE

    MSD’s Keytruda to be made available in England for advanced cervical cancer patients

    Around 2,600 people are diagnosed with cervical cancer each year in England

    - PMLiVE

    AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer

    More than 52,000 men are diagnosed with prostate cancer every year in the UK alone

    - PMLiVE

    AstraZeneca and MSD report final overall survival results from prostate cancer study

    The combination treatment increased the current patient survival rate by over seven months

    - PMLiVE

    MSD’s Keytruda plus chemotherapy approved in Scotland for advanced cervical cancer

    There were around 604,000 new cases and 342,000 deaths in 2020 from cervical cancer

    - PMLiVE

    AZ and MSD launch ‘Never Miss’ for prostate cancer awareness

    Prostate cancer is often symptomless and is the second most common cancer in men globally

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links